Literature DB >> 28757080

A Fusion Receptor as a Safety Switch, Detection, and Purification Biomarker for Adoptive Transferred T Cells.

Xiuqi Wu1, Bizhi Shi1, Jiqin Zhang1, Zhimin Shi2, Shengmeng Di1, Minliang Fan1, Huiping Gao1, Hai Wang1, Jianren Gu1, Hua Jiang3, Zonghai Li4.   

Abstract

The incorporation of an endogenous safety switch represents a rational strategy for the control of toxicities following the administration of adoptive T cell therapies. An ideal safety switch should be capable of depleting the transferred T cells with minimal injury to normal tissues. We generated a fusion receptor by engineering a cryptic 806 epitope of human epidermal growth factor receptor (EGFR) into the N terminus of the full-length human folate receptor 1 (FOLR1), designated as FR806. The expression of FR806 allows transduced T cells to be targeted with CH12, a monoclonal antibody recognizing the 806 epitope, but not wild-type EGFR in healthy tissues. FR806, therefore, constitutes a specific cell-surface marker for the elimination of transduced T cells. We demonstrate that the antibody-drug conjugate (ADC) CH12-MMAF is efficiently internalized by FR806-expressing T cells and has the potential to eliminate them. Transfected T cells could, furthermore, be efficiently detected and purified using CH12 antibodies. In immuno-compromised mice, CH12-MMAF eliminated the majority of transferred T cells expressing FR806 and anti-CD19 chimeric antigen receptor (CAR). The selectivity for the 806 epitope and internalization capacity of FOLR1 makes FR806 an efficient safety switch, which may additionally be used as a detection and purification biomarker for human T cell immunotherapies.
Copyright © 2017 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  gene therapy; gene transfer to lymphocytes; safety switch

Mesh:

Substances:

Year:  2017        PMID: 28757080      PMCID: PMC5628797          DOI: 10.1016/j.ymthe.2017.06.026

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  32 in total

1.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

2.  An inducible caspase 9 safety switch for T-cell therapy.

Authors:  Karin C Straathof; Martin A Pulè; Patricia Yotnda; Gianpietro Dotti; Elio F Vanin; Malcolm K Brenner; Helen E Heslop; David M Spencer; Cliona M Rooney
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

3.  A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.

Authors:  Xiuli Wang; Wen-Chung Chang; ChingLam W Wong; David Colcher; Mark Sherman; Julie R Ostberg; Stephen J Forman; Stanley R Riddell; Michael C Jensen
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

Review 4.  Targeted drug delivery via the folate receptor.

Authors:  J Sudimack; R J Lee
Journal:  Adv Drug Deliv Rev       Date:  2000-03-30       Impact factor: 15.470

5.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

6.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

7.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

8.  A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

Authors:  Andres Forero-Torres; John P Leonard; Anas Younes; Joseph D Rosenblatt; Pauline Brice; Nancy L Bartlett; Andre Bosly; Lauren Pinter-Brown; Dana Kennedy; Eric L Sievers; Ajay K Gopal
Journal:  Br J Haematol       Date:  2009-05-19       Impact factor: 6.998

9.  CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Authors:  Renier J Brentjens; Marco L Davila; Isabelle Riviere; Jae Park; Xiuyan Wang; Lindsay G Cowell; Shirley Bartido; Jolanta Stefanski; Clare Taylor; Malgorzata Olszewska; Oriana Borquez-Ojeda; Jinrong Qu; Teresa Wasielewska; Qing He; Yvette Bernal; Ivelise V Rijo; Cyrus Hedvat; Rachel Kobos; Kevin Curran; Peter Steinherz; Joseph Jurcic; Todd Rosenblat; Peter Maslak; Mark Frattini; Michel Sadelain
Journal:  Sci Transl Med       Date:  2013-03-20       Impact factor: 17.956

10.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.

Authors:  C Bonini; G Ferrari; S Verzeletti; P Servida; E Zappone; L Ruggieri; M Ponzoni; S Rossini; F Mavilio; C Traversari; C Bordignon
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728

View more
  4 in total

Review 1.  Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?

Authors:  David Kegyes; Catalin Constantinescu; Louise Vrancken; Leo Rasche; Celine Gregoire; Bogdan Tigu; Diana Gulei; Delia Dima; Alina Tanase; Hermann Einsele; Stefan Ciurea; Ciprian Tomuleasa; Jo Caers
Journal:  J Hematol Oncol       Date:  2022-06-07       Impact factor: 23.168

2.  Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma.

Authors:  Xingliang Guo; Hua Jiang; Bizhi Shi; Min Zhou; Honghong Zhang; Zhimin Shi; Guoxiu Du; Hong Luo; Xiuqi Wu; Yi Wang; Ruixin Sun; Zonghai Li
Journal:  Front Pharmacol       Date:  2018-10-01       Impact factor: 5.810

3.  An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment.

Authors:  Yi Wang; Hua Jiang; Hong Luo; Yansha Sun; Bizhi Shi; Ruixin Sun; Zonghai Li
Journal:  Front Immunol       Date:  2019-07-19       Impact factor: 7.561

Review 4.  Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review.

Authors:  Lærke J B Brandt; Mike B Barnkob; Yale S Michaels; Julia Heiselberg; Torben Barington
Journal:  Front Immunol       Date:  2020-02-26       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.